SMMT Summit Therapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:00
Aug 04
Aug 04
Comparisons to ivonescimab, which is partnered by Summit, implicitly benchmark Pfizer's drug against Summit's key asset.
HIGH
23:56
Aug 03
Aug 03
Summit Therapeutics speculative biotech with insider buying.
Summit Therapeutics has heavy insider buying ($50M by co-CEO, $5M by management), is awaiting FDA approval with trial results better than an existing drug, and can be treated as a speculative buy for risk-tolerant investors.
LOW
11:56
Jun 01
Jun 01
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs.
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs, causing chip competitors to fall and partners to gain, along with other corporate news including Berkshire Hathaway's acquisition of TMHC and FedEx completing its spin-off.
About SMMT Analyst Coverage
Buzzberg tracks SMMT (Summit Therapeutics) across 3 sources. 1 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (33%). 3 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: Chris Boshoff, Jim Cramer, Newsquawk.